Pharma Capital

Summit Therapeutics' US fundraiser should secure drug developer's long-term financial future

Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor
flag on the front of NYSE
The company is getting some traction for its story Stateside

Drug developer Summit Therapeutics PLC (LON:SMMT) will effectively secure its financial future with a fully underwritten issue of stock that could bring in as much as US$20mln.

The AIM-listed firm, which is also quoted on the NASDAQ exchange, is issuing 1.459mln new American depositary shares at US$12 each, bringing in a minimum of US$17.5mln.

A further 218,850 units are available to meet excess demand, which would take the total to US$20.1mln.

Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor.

US funding boost

The injection of investor cash follows news last week Summit had secured a funding package of US$62mln from US authorities to bankroll the development of its next-generation antibiotic, Ridinilazole. 

READ: Summit Therapeutics soars after securing funding from US government agency

Earlier this year it received a US$22mln milestone payment from the US biotech Sarepta related the progress of Ezutromid, its treatment for Duchenne Muscular Dystrophy (DMD), a rare muscle-wasting disease that affects boys.

Ezutromid recently completed enrolment for its PhaseOut phase II clinical trial, which triggered the payment from partner Sarepta.

Study underway

The study recruited 40 patients in the US and UK and will take 48 weeks to complete.

Researchers will assess how it affects muscle structure, health and function.

Data from the half-way stage is expected in the first quarter of next year with the trial set to close in the third quarter.

Blockbuster potential

Ridinilazole, meanwhile, could be a blockbuster for the company as well as providing a breakthrough against antibiotic resistance.

READ: Summit Therapeutics antibiotic delivers encouraging clinical trial results

It is thought to be effective against multiple different strains of the difficult-to-treat infection c.difficile (CDI).

It is also believed to be superior to existing medications such as vancomycin and metronidazole.

“We believe ridinilazole can become a new, urgently needed frontline therapy for this serious infectious disease,” said chief executive Glyn Edwards said recently

Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

View All

Related Articles

generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.